News articles about Neurocrine Biosciences (NASDAQ:NBIX) have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.5718801842235 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- $24.60 Million in Sales Expected for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) This Quarter (americanbankingnews.com)
- Neurocrine Biosciences Inc (finance.yahoo.com)
- Featured Company News – Mylan Launches Avonza(TM) in India (finance.yahoo.com)
- IHS Markit Score upgrades Neurocrine Biosciences Inc to 34 out of 100, despite ranking positively in only one IHS Markit category. (finance.yahoo.com)
- -$0.49 Earnings Per Share Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter (americanbankingnews.com)
Neurocrine Biosciences (NASDAQ:NBIX) opened at 54.07 on Friday. The stock’s 50 day moving average price is $48.53 and its 200-day moving average price is $46.79. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $55.38. The stock’s market cap is $4.77 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same quarter last year, the firm posted ($0.46) EPS. Equities research analysts predict that Neurocrine Biosciences will post ($2.45) EPS for the current year.
Several brokerages recently weighed in on NBIX. BMO Capital Markets increased their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a report on Friday, August 4th. Barclays PLC increased their price target on shares of Neurocrine Biosciences from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, May 2nd. ValuEngine upgraded shares of Neurocrine Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $62.00 price target on shares of Neurocrine Biosciences in a report on Monday, April 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $68.25.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 22,500 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the sale, the insider now directly owns 154,601 shares in the company, valued at $7,730,050. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Malcolm Lloyd-Smith sold 9,960 shares of the business’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $53.63, for a total value of $534,154.80. Following the sale, the insider now owns 17,997 shares in the company, valued at $965,179.11. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,194 shares of company stock worth $2,629,755. 4.80% of the stock is owned by company insiders.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.